UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1205-9
Program Prior Authorization/Notification – doxepin cream
Medication Prudoxin®* (doxepin), Zonalon®* (doxepin)
P&T Approval Date 12/2016, 12/2017, 12/2018, 1/2020, 3/2021, 3/2022, 3/2023, 3/2024,
4/2025
Effective Date 7/1/2025
1. Background:
Prudoxin and Zonalon cream are indicated for the short-term (up to 8 days) management of
moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus.
2. Coverage Criteriaa:
A. Initial Authorization
1. Prudoxin* or Zonalon* will be approved based on the following criteria:
a. Diagnosis of moderate pruritus due to one of the following:
(1) Atopic dermatitis
-OR-
(2) Lichen simplex chronicus
Initial authorization will be issued for 1 month
B. Reauthorization
1. Prudoxin* or Zonalon* will be approved based on both of the following criteria:
a. Diagnosis of moderate pruritis due to either atopic dermatitis or lichen simplex
chronicus
-AND-
b. Documentation of positive clinical response to therapy
Reauthorization will be issued for 1 month
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
* Brand Prudoxin and Zonalon are typically excluded from coverage.
© 2025 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Prudoxin [package insert]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.
2. Zonalon [package insert]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.
Program Prior Authorization/Notification – doxepin cream
Change Control
Date Change
12/2016 New program.
12/2017 Annual review with no changes.
12/2018 Annual review. Updated references.
1/2020 Annual review. Updated references.
3/2021 Updated to note brand Zonalon is typically excluded from coverage.
3/2022 Updated to note brand Prudoxin is typically excluded from coverage.
Added indication requirement to reauthorization section.
3/2023 Annual review. Added state mandate language.
3/2024 Annual review. No changes.
4/2025 Annual review. No changes.
© 2025 UnitedHealthcare Services Inc.
2